

Friday, 10th February 2017

	Opening Lecture Chairpersons: Karam Kostner and David Colquhoun
18:00 - 19:00	Lipid Lowering Therapy: Exciting New Developments and Challenges Peter Toth, Illinois, USA
19:00	Welcome Reception

Saturday, 11th February 2017

08:30 - 08:40	Opening Address: Karam Kostner and TBA
08:40 - 10:05	Plenary Session 1 Hot Topics : Novel Lipid Lowering Therapies Chairpersons: Gerald Watts and Stephen Nicholls
08:40 - 09:05	PCSK9 Inhibitors: Is It all about LDL or Do They Have Pleiotropic Effects? Stephen Nicholls, South Australia, Australia
09:05 - 09:35	Recent Lipid Lowering Trials that will Change Clinical Practice Stephen Nicholls, South Australia, Australia
09:35 - 10:05	Novel Lipid Lowering Therapies Gerald Watts, Western Australia, Australia
10:05 - 10:30	Coffee Break, Exhibition and E-poster Viewing

10:30 - 11:30	<p>Workshop 1 Statin Intolerance Chairs: Patrick M. Moriarty and David Hare</p>	<p>Workshop 2 Lipid Management in Diabetes and Chronic Renal Disease Chairs: Richard O'Brien and John Prins</p>
	<p>10:30 – 10:50: Definition of Statin Intolerance and Therapeutic Options David Sullivan, New South Wales, Australia</p> <p>10:50 – 11:10: Role of PCSK9 Inhibitors Giuseppe Danilo Norata, Milan, Italy</p> <p>11:10 – 11:30: Case Reports: all</p>	<p>10:30 – 10:50: How to treat Dyslipidemia of Diabetes Richard O'Brien, Victoria, Australia</p> <p>10:50 – 11:10: Risk Assessment in Diabetics- What Clinicians Need to Know Andrew Wilson, Victoria, Australia</p> <p>11:10 – 11:30: How to Treat Dyslipidemia in Renal Disease Nicole Isbel, Queensland, Australia</p>
11:30 - 13:00	<p>Plenary Session 2 Difficult to Treat Hyperlipidemia Chairpersons: Len Kritharides; Andrew Wilson</p>	
11:30 - 12:00	<p>Role of Ezetimibe Karam Kostner, Queensland, Australia</p>	
12:00 - 12:30	<p>Role of PCSK9-Inhibition Alberto Zambon, Padua, Italy</p>	
12:30 – 13:00	<p>Novel and forgotten Therapies Peter Toth, Illinois, USA</p>	
13:00 - 14:00	<p>SANOFI Satellite Lunch Symposium</p>	
14:00 - 15:00	<p>Workshop 3 Management of Paediatric Dyslipidemia Chairs: Robert Justo and Gary Leong</p>	<p>Workshop 4 Nutraceuticals, Complementary Medicine and Diet to Treat Hyperlipidemia Chairs: Paul Nestel and David Colquhoun</p>
	<p>14:00 – 14:20: When and How to Treat Dyslipidemia in Children Cases Robert Justo, Queensland, Australia</p> <p>14:20 – 14:40: LL Therapy in FH Children: When to start and which Agents? Shubha Srinivasan, New South Wales, Australia</p> <p>14:40 – 15:00: Case Reports: all</p>	<p>14:00 – 14:20: Dietary Fats: What is new? Paul Nestel, Baker IDI Heart & Diabetes Institute, Australia</p> <p>14:20 – 14:40: Which Nutraceuticals Work? David Colquhoun, Queensland, Australia</p> <p>14:40 – 15:00: Omega 3 Fatty Acids Trevor Mori, Western Australia, Australia</p>
15:00 - 15:30	<p>Coffee Break, Exhibition and E-poster Viewing</p>	
15:30 - 17:00	<p>Plenary Session 3 Imaging of Atherosclerosis Chairpersons: Stephen Nicholls and Christian Hamilton-Craig</p>	

15:30 – 16:00	Plaque Quantification and Atherosclerosis Regression Stephen Nicholls, South Australia, Australia
16:00 – 16:30	Role of Coronary Calcium Scoring Christian Hamilton-Craig, Queensland, Australia
16:30 – 17:00	Plaque Assessment in Clinical Practice Warrick Bishop, Tasmania, Australia
17:00 – 17:30	Special Book presentation and signing (by Dr Warrick Bishop)

Sunday, 12th February 2017

09:00 - 10:30	Plenary Session 4 Residual Risk: Lp(a)/HDL/TG Chairpersons: Philip Barter and Gerhard M. Kostner	
09:00 – 09:20	HDL: Risk Marker or Therapeutic Target? Philip Barter, New South Wales, Australia	
09:20 - 09:50	Combination of talk Anthony Keech, New South Wales, Australia	
09:50-10:10	Recent Lp(a) Apheresis Trials: Implications for Clinicians Patrick M. Moriarty, Kansas, USA	
10:10-10:30	When and How to Lower TG Anthony Keech, New South Wales, Australia	
10:30 - 11:00	Coffee Break, Exhibition and E-poster Viewing	
11:00 - 12:00	Workshop 5 Lipid Management in General Practice Chairperson: Chrys Michaelides; Mark Nelson	Workshop 6 Familial Hypercholesterolemia/Apheresis Chairpersons: Patrick M. Moriarty and Ian Hamilton-Craig
	11:00 11:20: Lipid Lowering Therapy in Elderly Patients Mark Nelson, Tasmania, Australia 11:20 – 11:40: Can Genetic Testing and Imaging Help GPs? David Richards, Queensland, Australia 11:40 – 12:00: Cardiovascular Risk Management in Remote Patients Rohan Corpus, Queensland, Australia	11:00 – 11:30: Diagnosis and Therapy of FH Ian Hamilton-Craig, Queensland, Australia 11:30 – 12:00: Apheresis and other Therapies Patrick M. Moriarty, Kansas, USA
12:00 - 13:00	Plenary Session 5 Global Initiatives and Genetics Chairpersons: David Sullivan; David Colquhoun	
12:00 – 13:00	What did we learn from Genetics and who do we test? David Sullivan, New South Wales, Australia Global Initiatives to Reduce The Burden of Disease: Need to Focus on Lipids David Colquhoun, Queensland, Australia	

13:00 - 14:00		AMGEN Satellite Symposium	
14:00 - 15:00	Workshop 7 Patient Advocacy and Registries Chairpersons: Gerald Watts; Julie Redfern	Workshop 8 Hyperlipidemia in Various Conditions Patients: Who and How to Treat Chairpersons: Stan Woodhouse; Michael D'Emden	
	14:00 - 14:30: Why are Registries important and how do they work? Gerald Watts, Western Australia, Australia 14:30 – 15:00: Engaging the Patients in the Age of Social Media Julie Redfern, New South Wales, Australia	14:00 - 14:15: Stroke and LL Therapy David Colquhoun, Queensland, Australia 14:15 - 14:30: Dyslipidemia in HIV Patients Andrew Redmond, Queensland, Australia 14:30 – 14:45: LL Therapy in Diabetes Michael D'Emden, Queensland, Australia 14:45 – 15:00: LL Fatty Liver Disease Marno Ryan, Victoria, Australia	
15:00 – 17:00	Abstract Session		
15:00 – 15:07	LDL Dynamics beyond simple delipidation: New Insights from Simultaneous Double Stable Isotope Tracer Kinetics Martin Jansen, Germany		
15:07 – 15:14	Current Dietary Guideline Advisory about Fat; Fact or De Facto Sam Mirzaee, Australia		
15:14 – 15:21	Benefits of L-thyroxine Replacement Therapy on Non-alcoholic Fatty Liver Disease in Subclinical Hypothyroidism Patients Lu Liu, China		
15:21 – 15:28	Vascular Health Promotion Program and Lipids Management in China Hongyu Wang, China		
15:28 – 15:35	Identifying families with Familial Hypercholesterolemia to prevent deaths due to premature Coronary Artery Disease in India Jitendrapal Singh Sawhney, India		
15:35 – 15:42	The Impact Of Weight-Loss In Obese Patients On Serum Lipids In The Recent Randomised Weight-Loss Cvd Endpoint Trials Matthew Laraghy, Australia		
15:42 – 15:49	The First Successful Direct Adsorption of Lipoproteins (DALI) Apheresis during pregnancy in an Omani Woman Suffering from Homozygous Familial Hypercholesterolemia Suad Al-Mukhani, Oman		
15:49 – 15:56	Lipid Metabolism In Workers Occupationally Exposed To Mercury Vapour Anna Skoczynska, Poland		
15:56 – 16:03	Toddlers With Hypercholesterolaemia - Management Challenges Shubha Srinivasan, Australia		
16:03 – 16:10	Children With Homozygous Familial Hypercholesterolemia (FH) On Lipoprotein Apheresis – A 3 Year Follow Up		

	Christina Tayan, Germany
16:10 – 16:17	Idiopathic Ductopaenia In A Paediatric Patient: A Case Report And Interesting Clinical Biochemistry Richard Ruddell, Australia
16:17 – 16:24	Antioxidant Property Of Hdl And Cholesterol Efflux Capacity Are Mutually Independent Risk Markers For Atherosclerotic Cardiovascular Disease In Patients With Familial Hypercholesterolemia Masatsune Ogura, Japan
16:24 – 16:31	Incidence Of Elevated Lipoprotein(A) Levels In A Very Large Community With Cardiac Disease Frank van Buuren, Germany
16:31 – 16:38	Benefit Of The PCSK9 Inhibitor Evolocumab In Patients Undergoing Lipid Apheresis Frank van Buuren, Germany
16:38 – 16:45	Investigation of Effect of Variant rs599839 Associated With SORT1 on LDL Subfractions and Severity of Coronary Artery Disease Hüseyin Avni Uydu, Turkey
16:45 – 16:52	The Triglyceride/High-density Lipoprotein Cholesterol Ratio Associates with Vulnerable Plaque Features on FD-OCT Imaging in Diabetic Patients Receiving a Statin Kohei Takata, Australia
16:52 – 16:59	Association of Large HDL Particles Concentrations with Favorable HDL Functionality in Adolescents Kohei Takata, Australia
16:59 – 17:06	Low Levels of High-density Lipoprotein Cholesterol do not Predict the Incidence of Type 2 Diabetes in an Iranian High-risk Population: The Isfahan Diabetes Prevention Study Mohsen Janghorbani, Iran
17:06 – 17:13	Lipid-Lowering Treatments Appear to Reduce Monocyte Inflammatory Profile in Familial Hypercholesterolaemia Stephen Li, Australia
17:13	Closing Remarks – Karam Kostner